Scott Megaffin, CEO, Adastra Pharmaceuticals has taken on the challenge of developing first-in-class innovative therapeutics for the treatment of cancers with high unmet needs such as high-grade gliomas.  He talks about the Phase 1b clinical trial conducted by the National Cancer Institute evaluating zotiraciclib, a potent oral cyclin-dependent kinase 9 inhibitor in combination with temozolomide in patients with recurrent brain cancer and possibly in the future to treat first-line glioma and other forms of glioma as well. #Glioblastoma #braintumor #drugdevelopment #braincancer #NCI AdastraRx.com Download the transcript here